PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy shows promise against tough cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had minimal residual disease after standard treatment. The goal was to see if the treatment is safe and can re…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
Pancreatic cancer study seeks best Post-Surgery combo
Disease control CompletedThis study looked at 546 people whose pancreatic cancer was removed by surgery. It tested whether adding a targeted drug (erlotinib) or radiation therapy to standard chemotherapy could help them live longer. The goal was to find the best way to kill any remaining cancer cells aft…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:27 UTC
-
New hope for pancreatic cancer: drug combo shows promise in trial
Disease control CompletedThis study tested a new drug called onvansertib combined with standard chemotherapy for people with advanced pancreatic cancer that had spread. The goal was to see if the combination could shrink tumors or slow the disease. 41 adults who had already tried one type of chemotherapy…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Cardiff Oncology • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New imaging agent could help match pancreatic cancer patients to the right therapy
Diagnosis CompletedThis early-phase study tested a new PET imaging agent (64Cu-DOTA-ECL1i) in 69 people with pancreatic cancer to see if it can detect a specific marker (CCR2) on tumors. The goal was to find out whether the scan can predict how well a patient will respond to standard chemotherapy o…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Apr 29, 2026 15:05 UTC
-
New PET scan could sharpen detection of stomach, liver, and colon cancers
Diagnosis CompletedThis study tested a new type of PET scan called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The scan looks for a protein called FAP that is often found on cancer cells. Researchers compared the s…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: SOFIE • Aim: Diagnosis
Last updated Apr 29, 2026 15:02 UTC
-
Personalized chemo for pancreatic cancer: a step closer?
Knowledge-focused CompletedThis study looked at 150 people with advanced pancreatic cancer that had spread. It compared two standard chemotherapy treatments to see which works better and used lab tests to find markers that could predict the best treatment for each person. The goal was to improve how we cho…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:49 UTC